Indication
T-cell lymphoma
9 clinical trials
10 products
1 drug
Product
No interventionClinical trial
Real-World Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma PatientsStatus: Recruiting, Estimated PCD: 2024-06-30
Product
LB1901Clinical trial
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 4, Single Arm, Open Label, Multicenter Study of Brentuximab Vedotin Treatment of Chinese Patients With CD30-Positive Cutaneous T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
Brentuximab vedotinClinical trial
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2018-06-01
Product
ASN002Clinical trial
Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasStatus: Completed, Estimated PCD: 2023-01-11
Product
LenalidomideClinical trial
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell LymphomaStatus: Recruiting, Estimated PCD: 2028-04-30
Product
PembrolizumabClinical trial
Observational Clinical Study of Autologous Hematopoietic Stem Cell Transplantation and Chemotherapy as First-Line Consolidation Therapy After Obtaining a Complete Therapeutic Response in T-Cell LymphomaStatus: Completed, Estimated PCD: 2022-01-01
Product
Consolidation with ASCTDrug
CarfilzomibProduct
RomidepsinClinical trial
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Product
RuxolitinibProduct
DuvelisibClinical trial
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasStatus: Recruiting, Estimated PCD: 2027-07-31